HOLLYWOOD, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- NV5, a provider of technology, certification, and consulting solutions, announced today that it has been awarded over $20 million in engineering design and construction management contracts by the New York City Department of Parks and Recreation to support parks and recreation facility improvements. These awards continue NV5's 20-year relationship designing and overseeing the construction of New York City's more than 1,700 parks and recreational spaces. Thi ...

LONDON, June 30, 2025 (GLOBE NEWSWIRE) -- Ferroglobe PLC (NASDAQ: GSM), a leading global producer of silicon metal, silicon-based and manganese-based specialty alloys, announces its inclusion in the Russell 2000® and Russell 3000® Indexes effective today. The Russell US indexes, maintained by FTSE Russell, capture the 3,000 largest U.S. stocks as of April 30 each year, ranking them by total market capitalization. Membership in the Russell 3000® Index brings automatic inclusion in either the large-cap Russel ...

Strategic divestiture aligns resources toward high-growth technology and aircraft trading initiatives ATLANTA, GA, June 30, 2025 (GLOBE NEWSWIRE) -- Volato Group, Inc. (the “Company” or “Volato”) (NYSE American: SOAR), a technology-driven private aviation company, today announced the completed sale of GC Aviation, Inc. (“GC Aviation”) for $2 million in cash. The transaction included the transfer of GC Aviation’s FAA Part 135 air carrier certificate, under which Volato had conducted its managed aircraft oper ...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical- stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member of the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of U.S. equity markets today, June 30, 2025. "Protara's inclusion in the Russell 3000 Index is a reflection of the progress that we have made executing acro ...

Core-Mark National Authorization, Walmart Canada Breakthrough, and Key Regional Wins Highlight Rapid Growth in Functional Beverage and Supplement Categories WESTBROOK, Maine, June 30, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) ("Synergy" or the "Company"), a fast-growing consumer health and wellness company, today announced a major wave of North American retail and distribution gains across both its supplement and functional beverage portfolios. These wins represent the Company's most signifi ...

First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced favorable results from its first-in-human ...

TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Topicus.com Inc. (the “Corporation”) (TSXV: TOI) today announced that its subsidiary, Topicus.com Coöperatief U.A., has successfully obtained a €200 million senior unsecured Schuldschein loan. The Schuldschein loan was initially launched at €100 million and was subsequently doubled on the back of significant interest from institutional lenders. The Schuldschein loan is structured in several tranches at variable rates, with €79.5 million maturing in 3 years, €105.5 m ...

Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award from the Cancer Prevention & Research Institute of Texas HOUSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, toda ...

文章核心观点 - 百健公司宣布启动全球临床研究PROMINENT，评估felzartamab对比他克莫司治疗原发性膜性肾病（PMN）的疗效和安全性，felzartamab有潜力为PMN患者带来新治疗选择 [1][3] 分组1：研究介绍 - PROMINENT研究为104周、随机、开放标签、全球多中心的3期试验，预计招募约180名PMN成人患者，2029年得出结果，旨在评估felzartamab对比他克莫司在中高风险PMN参与者中实现蛋白尿完全缓解的疗效和安全性 [1][3] - 研究主要终点为第104周实现完全缓解（CR）的参与者百分比，将评估抗PLA2R（aPLA2R）自身抗体阳性和阴性患者，并根据PLA2R水平分层，关键次要终点包括felzartamab对血清抗磷脂酶A2受体（PLA2R）抗体的影响和患者报告结局 [3] 分组2：药物介绍 - felzartamab是一种抗CD38抗体，临床研究显示其能选择性耗竭CD38+细胞，包括浆细胞，高达80%的PMN患者有由表达CD38的浆细胞产生的针对PLA2R的自身抗体（aPLA2R） [2] - felzartamab此前在两项2期研究M - PLACE（n = 31）和NewPLACE（n = 24）中进行了研究，在M - PLACE最终分析中，多数患者早在一周时就观察到aPLA2R滴度降低（中位降低45%），六个月治疗结束时多数患者有反应（降低>50%），同时观察到蛋白尿和血清白蛋白水平改善 [4] - 两项研究中报告的大多数治疗突发不良事件（TEAE）为轻度至中度，与felzartamab在PMN人群中的已知作用机制一致，最常见的TEAE是首次输注时的输液相关反应，强度大多为轻度至中度 [4] 分组3：疾病介绍 - PMN是一种严重的抗体介导的肾脏疾病，是肾病综合征的主要原因，有显著肾衰竭风险，美国估计患病率约为3.6万患者，目前尚无获批治疗方法，标准治疗包括免疫抑制剂到化疗，约三分之一患者无法实现缓解 [1][9] 分组4：公司介绍 - 百健成立于1978年，是一家领先的生物技术公司，致力于开创创新科学，提供新药以改变患者生活，为股东和社区创造价值，通过深入了解人类生物学和利用不同模式推进首创疗法或带来卓越疗效的疗法 [10] 分组5：其他信息 - 除了启动felzartamab治疗PMN的3期研究，百健今年还启动了另外两项felzartamab的3期研究，分别是针对成人肾移植受者晚期抗体介导排斥反应的TRANSCEND和针对IgA肾病的PREVAIL [5]

文章核心观点 - 全球能源和工业气体解决方案领导者Chart Industries公司计划于2025年7月31日上午8:30举行电话会议讨论2025年第二季度财务结果，并将在当日开盘前发布财报 [1] 会议安排 - 会议时间为2025年7月31日上午8:30 ET [1] - 参与者可通过北美免费电话(+1) 800 549 8228或北美及其他地区收费电话(+1) 289 819 1520加入直播问答环节 [2] - 公司投资者关系网站将提供直播网络广播、回放及演示幻灯片，链接为Q2 2025 Webcast Registration [2] - 电话会议结束约两小时后可通过1 - 888 - 660 - 6264及密码51851收听电话回放，直至2025年8月7日 [2] 公司介绍 - 公司是气体和液体分子处理工艺技术和设备设计、工程和制造的全球领导者，产品和解决方案用于液化气供应链各阶段 [3] - 公司是液化天然气、氢气、沼气和二氧化碳捕获等技术、设备和服务的领先供应商 [3] - 公司在全球有64个制造基地和50多个服务中心，分布于美国、亚洲、澳大利亚、印度、欧洲和南美 [3] 投资者联系方式 - 高级副总裁John Walsh，电话770 - 721 - 8899，邮箱john.walsh@chartindustries.com [4]